BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update. Areas to watch include next-generation checkpoint targets, where...
BioCentury | Dec 8, 2018
Product Development

Intermittent move beyond Blincyto

A swath of data at ASH shows that companies have been able to move beyond the 28-day continuous dosing of Amgen Inc.’s first-generation BiTE, Blincyto, to build next-generation antibodies with more convenient, intermittent dosing and...
BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
BC Extra | Jul 26, 2018
Company News

Reese succeeding Harper as Amgen EVP of R&D

Amgen Inc. (NASDAQ:AMGN) said EVP of R&D Sean Harper will retire and be succeeded by SVP of Translational Sciences and Oncology David Reese. The company also reported 2Q18 earnings on Thursday after market hours that...
BC Week In Review | Jul 28, 2017
Company News

Amgen gets rights to Captisol formulation technology for BiTE AMG 330

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) granted Amgen Inc. (NASDAQ:AMGN) exclusive, worldwide commercialization rights to combine Captisol formulation technology with AMG 330 to treat multiple indications. Ligand received an undisclosed upfront payment and is eligible for milestones...
BC Extra | Sep 17, 2015
Company News

Amgen, Xencor partner on bispecific antibodies

Amgen Inc. (NASDAQ:AMGN) and Xencor Inc. (NASDAQ:XNCR) partnered to develop six preclinical programs in cancer and inflammation using Xencor's XmAb bispecific antibody platform. Xencor President and CEO Bassil Dahiyat told BioCentury that Xencor will use...
Items per page:
1 - 6 of 6